Cancer, 2L PI3Kα-mutated, HR+/HER2- locally advanced or metastatic breast cancer
RLAYRelay TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for RLY-2608 + fulvestrant (doublet) in Cancer, 2L PI3Kα-mutated, HR+/HER2- locally advanced or metastatic breast cancer. The expected timing is based on the latest available company guidance and may change.
ReDiscover trial. 9/9/24- Announced interim data. 12/11/24- Reported new interim data at SBCS'24. 6/2/25- Reported updated data at ASCO '25. 11/06/25:- PR No update. 12/12/25:- SABCS 2025 subset analysis: zovegalisib+fulvestrant showed 10.3-month median PFS and 39% ORR in ReDiscover. 02/03/26:- Breakthrough Therapy designation granted. Initial Ph1/2 400mg BID fed doublet data at ESMO TAT on March 16, 2026. 02/26/26:- ESMO TAT 2026 session will present initial ReDiscover Ph1/2 doublet data on 57 patients. 03/16/26:- ReDiscover Ph1/2 400mg BID fed data: median PFS 11.1 months; ORR 43%; tolerability consistent. 05/05/26:- ESMO TAT doublet data reiterated: median PFS 11.1 months, similar efficacy across kinase and non-kinase mutations. 08/06/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.